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Background: The value of re-exploration for pancreatic ductal adenocarcinoma after the
initial diagnosis of unresectability is unclear.
Methods: In this study, we analyzed 33 patients who were re-explored after an initial
diagnosis of unresectability.
Results: At the time of reoperation, a resectable tumor was found in 18 patients: therefore,
15 pancreaticoduodenectomies, two total pancreatectomies and one left resection were per-
formed with three vascular resections. Morbidity and mortality rates for the cohort were 6/33
and 1/33, without signiﬁcant differences between resectable and nonresectable patients.
Length of stay, duration of operation, and blood loss were signiﬁcantly increased in the
resection group. Kaplan–Meier survival analysis demonstrated increased median survival for
resected patients (1078 days after the initial operation versus 547 days in the group of unre-
sectable patients; p = 0.018). Analysis of the reasons against initial resection showed that, if
the patients had been sent to a tertiary referral center for pancreatic surgery, a different
decision in favor of resection would probably have been made in 14 out of 33 patients. A
review of 10 published reports on reoperation for pancreatic cancer revealed results compa-
rable to our study in terms of low morbidity and mortality as well as a survival beneﬁt.
Conclusions: Reoperation for pancreatic ductal adenocarcinoma that is initially deemed
unresectable can be safely performed in a selected group of patients by experienced surgeons,
supporting the concept of patient centralization in pancreatic surgery. Resection at the second
operation may confer a survival beneﬁt even when the initial ﬁndings preclude a potentially
curative approach.
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Surgical resection is the only curative approach
available for patients suﬀering from pancreatic can-
cer.
1 However, resection rates remain low, not only
because advanced disease is present in the majority of
patients, but also because nonspecialized centers of-
ten have insufﬁcient experience with radical sur-
gery.
2–4 Resection rates in tertiary referral centers are
increasing due to technical progress, improved peri-
operative management, increasing emphasis on a
more-radical approach, such as resection of tumor-
inﬁltrated portal vein, and improved experience in
judging resectability.
3,5–8 This holds particularly true
for evaluating vascular inﬁltration, which may pre-
clude resection. In these cases, extensive mobilization
and careful dissection are necessary to distinguish
accompanying inﬂammatory adhesions from tumor
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186inﬁltration of retroperitoneal vessels. However,
determination of resectability remains challenging,
and thus in selected cases less-experienced surgeons
are potentially more prone to mistakenly regard a
tumor as unresectable.
Since randomized trials on the value of neoadju-
vant therapy have not yet been published, it also re-
mains unclear whether—particularly in younger
patients—neoadjuvant treatment (or reoperation
after initially palliative chemotherapy) may be bene-
ﬁcial, at least in some patients, and may thus lead to
resectability of an initially unresectable tumor.
Reoperation of patients who were deemed unre-
sectable may be a further option to increase resection
rates.
9–18 The value of re-exploration has only been
analyzed by a few groups: 10 studies have addressed
this question, with the ﬁrst study concluding that an
‘‘appreciable salvage rate’’ is feasible on re-evalua-
tion.
9 Subsequent studies conﬁrmed these results and
demonstrated that a second-look operation can be
performed with low morbidity and mortality rates,
and that this approach confers a survival beneﬁt for
the then resectable patients.
10–18 Calculations of sta-
tistically signiﬁcant differences in survival of resected
and unresected patients at reoperation are hampered
by insufﬁcient power of the individual studies due to
small patient groups. However, there is a general
trend showing that re-exploration may be an option
in carefully selected patients at specialized centers.
In this study, we retrospectively analyzed our sin-
gle-center experience with a group of patients who
had initially been diagnosed as unresectable and who
were subsequently referred to us for re-exploration.
In addition, a literature review of the available (ret-
rospective) studies was performed to more precisely
deﬁne the value of re-exploration.
PATIENTS AND METHODS
From our database we identiﬁed 33 patients with
ductal adenocarcinoma of the pancreas who had
initially been diagnosed as unresectable (at other
institutions) but were re-explored in the course of
their disease. Patient characteristics, initial proce-
dures, subsequent palliative or neoadjuvant thera-
pies, operative details of the re-exploration,
morbidity, and mortality (death within 30 days after
surgery) were prospectively recorded. Patients were
followed up until February 2007. At the time of
analysis, two out of 14 patients in the group of un-
resectable patients and 11 out of 19 patients in the
resection group were alive.
During the second-look operation, resectability
was deﬁned using previously reported criteria.
1 If
resection was impossible, a tumor biopsy was taken
from those patients in whom the initially performed
palliative operation was sufﬁcient. In the case of an
obstruction, a gastroenterostomy, hepaticojejunos-
tomy or a double bypass procedure was performed.
In resectable patients, a pylorus-preserving pancrea-
ticoduodenectomy (ppPD) was the standard opera-
tion. However, if the tumor involved the pyloric
region, a classical PD was carried out. To achieve
tumor-free resection margins, a total pancreatectomy
had to be performed in two cases. A distal pancrea-
tectomy was performed for one tumor of the tail of
the pancreas.
Pancreatic tumors other than ductal pancreatic
adenocarcinoma were excluded. The specimens from
resectable (at reoperation) patients were classiﬁed
according to the tumor, node, metastasis (TNM)
classiﬁcation.
19
For the preoperative imaging of operable patients,
computed tomography of the abdomen or magnetic
resonance imaging/magnetic resonance cholangio-
pancreaticography (MRI/MRCP) was the standard.
Statistical Analysis
The Kaplan–Meier method was used for presen-
tation of the survival curve, and differences in sur-
vival were evaluated with the log-rank test. A P value
of < 0.05 was regarded as statistically signiﬁcant.
Literature Review
A literature search was performed independently
by CWM, JK, and JB as described previously.
20 The
last search was carried out on 30 January 2007.
Available manuscripts were cross-searched to identify
studies that had not initially been found. The search
strategy revealed 10 retrospective studies on re-
exploration after initial diagnosis of unresectability.
No stratiﬁcation was performed because only retro-
spective analyses have been published. Data collec-
tion was conducted as previously described.
20
RESULTS
In this study, 33 patients (median age 60 years)
from our prospectively maintained database who had
been re-explored after having initially been deﬁned as
unresectable (operation between 2001 and 2005) were
included. At the time of the initial operation, an
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patients, while in the other 49% a bypass operation or
a biopsy was carried out (Table 1). The main reason
for the deﬁnition of unresectability at the initial
operation was vascular inﬁltration (six arterial inﬁl-
trations, nine venous inﬁltrations). In some patients,
metastatic disease was present (Table 2). After the
ﬁrst operation, most patients received palliative/
neoadjuvant therapy. The types of treatment varied
considerably: 13 patients received chemoradiation, 12
patients were treated with chemotherapy, and eight
patients received no therapy. There were no stan-
dardized treatment protocols for palliative/neoadju-
vant therapy, but patients were treated according to
local guidelines at the institution where the initial
diagnosis had been made.
Upon referral to our department, all patients pre-
sented in adequate general condition (ASA score £ 3;
American Society of Anesthesiologists). At the sec-
ond operation, 18 patients were found to have a
resectable tumor, while in 15 patients the primary
tumor could not be resected. The median time from
initial surgery to re-exploration was 88 days in the
unresectable group and 101 days in the group of
patients in whom a resection could be performed.
Except for one patient with a large tumor inﬁltrating
the retroperitoneal vessels, metastatic disease (not
detectable in the abdominal CT scan) was present in
all the unresectable patients, precluding a surgical
resection (Table 4).
In the group of patients who were found to be
resectable, 15 pancreaticoduodenectomies, two total
pancreatectomies and one distal pancreatectomy
were performed (Table 3). Portal vein/superior mes-
enteric vein (SMV) resections had to be carried out in
four patients. There was one patient with a liver
metastasis at the initial operation (Table 2) who was
resected at the second-look surgery. The patient had
no liver metastases at the second look and was
therefore considered resectable. This patient is alive
at 1241 days after the initial surgery. Four out of ﬁve
patients without neoadjuvant treatment who were
resected (Table 1) received adjuvant chemotherapy.
One patient refused adjuvant treatment.
In the group of unresectable patients, bypass pro-
cedures were carried out in eight patients, while seven
patients underwent exploration with tumor biopsy
(Table 3).Thepostoperativecourseofthepatientswas
mostly uneventful, with two morbidities in the inop-
erablegroupandﬁveintheresectedpatients(Table 3).
One patient who was resected died in the immediate
postoperative period (mortality 1/18). The duration of
theoperation,amountofbloodloss,andlengthofstay
were increased in the resection group (Table 3).
TABLE 1. Patient characteristics
Unresectable
patients (n = 15)
Resectable
patients (n = 18)
Age 60 (41–68) 61 (33–71)
Female 3 4
Male 12 14
Initial operation
Explorative laparotomy 4 8
Gastroenterostomy 5 0
Double bypass 3 5
Lymph node biopsy 1 0
Resection of abdominal
wall tumor
10
Laparoscopy 0 2
Hepaticojejunostomy 1 3
Interval between
surgeries (median)
88 days 101 days
Preoperative tumor markers
CA19-9 (median) 608 U/l 117 U/l
CEA (median) 39143 U/l 136 U/l
Diabetes mellitus 3 6
Neoadjuvant therapy 12 13
TABLE 2. Criteria for initial inoperability
Unresectable
patients (n = 15)
Resectable
patients (n = 18)
Peritoneal metastasis 4 0
Vascular inﬁltration 6 9
Liver metastasis 3 1
Duodenal inﬁltration 1 1
Lymph node inﬁltration 1 4
Other/unknown 0 3
TABLE 3. Surgical procedures at second operation, mor-
bidity and mortality
Unresectable
patients
(n = 15)
Resectable
patients
(n = 18)
Exploration with biopsy 7 –
Double bypass 3 –
Gastroenterostomy 3 –
Hepaticojejunostomy 2 –
Pancreaticoduodenectomy – 5
Pylorus-preserving
pancreaticoduodenectomy
–1 0
Total pancreatectomy – 2
Left resection – 1
Duration of operation (min; median) 105 440
Blood loss (ml; median) 100 500
Morbidity 2 3
Delayed gastric emptying 1 0
Bilioma 1 0
Wound dehiscence 0 1
Cholangitis 0 1
Lymph ﬁstula 0 1
Mortality 0 1
Length of stay (days; median) 11 12
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present in most of the cases. Only one patient was
found with a T2 tumor. Nine pancreatic specimens
(50%) were node positive, with an average of 21.5
harvested lymph nodes. A grade 1 tumor was found
in only two patients, whereas a grade 2 tumor was
present in nine patients and a grade 3 pancreatic
cancer was present in seven patients.
The Kaplan–Meier survival curves revealed a
median survival of 439 days for unresectable patients
versus 934 days for resected patients (after the second
operation). A log-rank test demonstrated that this
difference was statistically significant (P = 0.013;
data not shown). To better judge the inﬂuence of
neoadjuvant/palliative treatment on survival, a
Kaplan–Meier curve was calculated for the survival
after the initial operation. This analysis showed a
significantly different median survival of 547 versus
1078 days for unresectable versus resectable patients
(P = 0.018; Fig. 1).
To judge whether resection at reoperation inﬂu-
ences the outcome, we compared re-resected (18) and
non-re-resected (15) patients with a cohort of 554
patients who were resected at the initial operation at
our center and with a cohort of 250 patients who
could not be resected. The Kaplan–Meier survival
curve followed by a log-rank test revealed no differ-
ences in survival (P = 0.2514; Fig. 2) when com-
paring initially resected patients and patients resected
at the second operation. Furthermore, there were also
no differences in comparison of the unresectable pa-
tients, irrespective of the second surgery (P = 0.45;
Fig. 3).
Subsequently, we performed a retrospective review
of the causes of initial unresectability. This revealed
that only 11 of 33 patients had initially been treated
at a high-volume center (deﬁned as hospitals with a
case load of >16 pancreatic resections per year
7).
Except for four cases with metastasized disease,
inﬁltration of local structures was the main reason for
initial unresectability. A detailed analysis of these
causes of unresectability showed that 14 of 33 pa-
tients would probably have been resected if they had
initially been referred to our center. In these cases,
mainly venous (SMV/PV) inﬁltration was present,
which may not be considered a contraindication for a
resection.
Review of Retrospective Studies
Ten studies on the value of re-exploration to
potentially achieve resection have been published so
far.
9–18 In the ﬁrst study, by Moosa,
9 17 patients were
re-evaluated after having initially been diagnosed as
unresectable. Of these, nine patients underwent total
pancreatectomy, while in two patients no tumor was
detectable. The survival of the resected cohort was
1.5–6 years, which was higher than the mean survival
in the group of patients with inoperable disease (7–12
months). Similar results were reported by Hashimi et
al., who performed a second-look operation on 30
patients, revealing that nine were resectable, while in
two patients no tumor was found despite several
biopsies.
11 In the study by Jones and co-authors,
preliminary surgery (nonresective) had been carried
out before referral in 51% of the patients, leading to
the correct diagnosis in only 44% of these.
10 How-
ever, outcomes for this patient cohort are not spe-
ciﬁcally described. Two publications from the Johns
Hopkins Institutions also extensively describe results
obtained in re-exploratory surgery of two patient
cohorts (recruited at different time periods: from
1979 to 1990 and from 1991 to 1997). In the ﬁrst
publication,
12 the resection rate for pancreatic cancer
at re-exploration was 58%, with subsequent mean
survival periods of 20.5 months (pancreatic adeno-
carcinoma) and 33 months (nonpancreatic periam-
pullary malignancies), which were comparable to the
cohort of initially resectable patients. Sohn et al.
subsequently described results obtained from re-
exploration of a second cohort of patients that in-
cluded all periampullary tumors.
16 The resection rate
at reoperation was 67%. There was a striking survival
difference when comparing the unresectable and the
resectable groups (at re-exploration), with a median
survival of 7 versus 23 months, respectively. Com-
parison of the patients who were resected at re-
exploration with a control group who had initially
been resected revealed signiﬁcantly increased survival
rates in the reoperative group (Kaplan–Meier sur-
vival curve generated from the time of initial opera-
tion: 20 months in the control group versus 33
months in the reoperative group, P = 0.02). In the
study by Tyler et al. from 1994, reoperation rates
were comparable with the earlier published studies
(14 out of 19 patients who underwent re-laparotomy
were resected), as were the (low) complication rates
TABLE 4. Criteria for unresectability at reoperation
Unresectable
patients (n = 15)
Peritoneal metastasis 6
Liver metastasis 5
Omental metastasis 1
Peritoneal and liver metastasis 2
Retroperitoneal inﬁltration 1
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13 At the time of
median follow-up of 26 months, four of ten patients
with pancreatic adenocarcinoma were alive, suggest-
ing survival rates comparable to previously published
results. Similarly, Johnstone and Sindelar showed a
resection rate of 55% at re-exploration and signiﬁ-
cantly improved disease-speciﬁc survival rates in the
resected group (P < 0.01)
14. Robinson and co-
workers demonstrated an exceptionally high resec-
tion rate at reoperation of 100%.
15 In a study by
Chao and co-workers, a resection rate at the second
look operation of 55% was shown.
18 Furthermore,
they could demonstrate that resection at the second
operation led to ‘‘a median survival comparable with
that of patients who did not undergo previous
exploration’’. In the most recently published study,
by Shukla et al., all patients who were reoperated
could be resected.
17 Conﬁrming the previously pub-
lished studies, low morbidity and mortality rates were
demonstrated.
TABLE 5. Review of studies on re-exploration for pancreatic cancer
Author Year Institution Patients Resection rate
Moosa 1979 University of Chicago 24 17/24 (71%)
Jones 1985 University of Toronto 50 N/A
Hashimi 1989 Bradford Royal Inﬁrmary 26 11/26 (42%)
McGuire 1991 Johns Hopkins Medical Institutions 55 33/55 (60%)
Tyler 1994 M.D. Anderson Cancer Center 19 14/19 (74%)
Robinson 1996 M.D. Anderson Cancer Center 29 29/29 (100%)
Johnstone 1996 Naval Medical Center, San Diego 29 16/29 (55%)
Sohn 1999 Johns Hopkins Medical Institutions 78 52/78 (67%)
Chao 2000 Fox Chase Cancer Center 40 22/40 (55%)
Shukla 2005 Tata Memorial Hospital, India 15 15/15 (100%)
This series 2007 University of Heidelberg 33 18/33 (55%)
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FIG. 1. Kaplan–Meier survival curve of re-explored patients after
initial operation. Comparison of the survival curves of re-explored,
resected patients (n = 17; one excluded due to postoperative
mortality; red) and re-explored, unresectable patients (n = 15;
black). A log-rank test demonstrated signiﬁcantly increased sur-
vival in the resected patients (P = 0.018).
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FIG 2. Survival curves of re-explored, resected patients and 572
primarily resected pancreatic ductal adenocarcinoma (PDAC) pa-
tients. Comparison of the survival curves of re-explored, resected
patients (n = 18; red) and a control cohort of 572 patients (black)
who were initially resected revealed no differences regarding sur-
vival (P = 0.2514).
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FIG. 3. Overall survival of re-explored, unresectable patients and
256 unresectable patients. The survival of a control cohort of 256
PDAC patients who were unresectable (n = 265) was compared
with re-explored, unresectable patients (n = 15; red), revealing no
differences in survival (P = 0.45).
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This single-center experience shows that re-explo-
ration of patients initially deemed unresectable may
be an option for the treatment of pancreatic cancer.
In concordance with previously published studies
(which were all retrospectively conducted), re-explo-
ration can yield resectability rates greater than 50%
and can be performed with low morbidity and mor-
tality. However, whether reoperation confers a sur-
vival beneﬁt is still a matter of discussion.
Although diagnosis of resectability has been facili-
tated by the use of multidetector, high-resolution
computed-tomography exploration often remains
necessary.
21,22 Particularly when neoadjuvant therapy
has been applied, ﬁbrosis and an inﬂammatory reac-
tion frequently hamper exact assessment of tumor size
and(potential)metastaticdisease.Anumberofstudies
havedemonstratedthatboththecomplicationrateand
mortality after pancreatic surgery are signiﬁcantly
higher in hospitals that perform few operations.
3,7,8
We found that, upon re-exploration, more thanhalfof
the tumors were resectable, and that 42% of the pa-
tients initially deemed unresectable could have been
resected at high-volume centers. These results support
theconceptthatpatientswithpancreaticcancershould
be treated with an interdisciplinary approach at large
tertiary referral centers.
Furthermore, resection in a second-look operation
was shown to potentially confer a survival beneﬁt, al-
though it remains unclear whether this is due to
resection or to favorable tumor biology in the patients
in whom a regression of the initially metastasized or
inﬁltrating tumor was achieved. Altogether, there was
signiﬁcantlyincreasedsurvivalinthereoperatedgroup
of patients compared with a control cohort of patients
who were not reoperated (resected and unresectable).
These results suggest that there might be a generally
favorable tumor biology in this group of reoperated
patients.However,thediﬀerencesinsurvivalconferred
byresectionatreoperationconﬁrmthenotionthatina
subgroupofpatientsingoodcondition,re-laparotomy
(and potentially resection) should be attempted. Fur-
thermore, reoperated but not resected patients do not
fare worse than those who were not resected initially
and who were not explored again after chemotherapy
or chemoradiation. Therefore, we again conclude that
inaselectedcohortofpatientswithatendencytowards
remission, re-laparotomy may be a valid option. This
holds particularly true when patients have initially
been considered unresectable at smaller hospitals with
less experience in pancreatic surgery and especially
with less experience in judging whether a tumor is
resectable. This is supported by many studies on re-
operative pancreaticoduodenectomy for pancreatic
cancer.
12,13,15–17 As stated by Robinson and co-au-
thors, ‘‘detailed preoperative imaging and a clearly
deﬁned operative plan would have allowed successful
resection at the initial operation’’ in the majority of
patients. However, accompanying inﬂammatory
changes allow judgment of resectability only during
the surgical procedure itself in many cases. Therefore,
not only preoperative assessment but also the exten-
sion of resectability criteria (as present in high-volume
centers) is a key factor for improving the outcome in
patients with pancreatic cancer. We strongly suggest
that all patients suffering from pancreatic cancer
should be referred to high-volume centers. Further-
more, patients in generally good condition but locally
unresectable disease should receive neoadjuvant
chemoradiation, preferably within randomized con-
trolled clinical trials.
23 However, we do not consider
inﬁltration of the SMV/portal vein (in contrast to
superior mesenteric artery (SMA)/celiac trunk
involvement) a contraindication for resection. Fol-
lowing the last cycle of chemoradiation, high-resolu-
tion CT will allow judging resectability in many cases
and in the absence of metastatic disease, surgical
exploration remains the only option to determine
resectability.
In conclusion, reoperation for pancreatic cancer
after initial classiﬁcation of unresectability revealed
resectability in half of patients. Since the majority
had received chemotherapy/chemoradiation after the
initial operation, the concept of selecting patients by
neoadjuvant therapy may be supported. Further-
more, a subgroup analysis revealed that a large
number of patients who were initially deemed unre-
sectable at smaller hospitals would have been resect-
able at a large tertiary referral center, which again
promotes the concept of patient centralization in
pancreatic surgery. A survival beneﬁt for the resected
patients underlines the eﬃcacy of a surgical resection
even in a situation in which the initial ﬁndings pre-
clude a potentially curative approach.
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